Clinical Trial Update: Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia [Phase 1]

View source ↗

Summary

Phase 1 trial update on an rHSA/GCSF fusion protein for injection shows safety and preliminary efficacy data in treating neutropenia, studied in cancer patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neutropenia

Drugs mentioned

• rHSA/GCSF Fusion Protein (recombinant human serum albumin granulocyte colony-stimulating factor fusion protein)

Snippet

Sponsor: Tianjin SinoBiotech Ltd. | Conditions: Underdose (Unintentional), Cancer | Phase 1 | Status: COMPLETED